- Title
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- Creators
- Bradley J. Monk (Author) - Creighton UniversityAndrés Poveda (Author)Ignace Vergote (Author)Francesco Raspagliesi (Author)Keiichi Fujiwara (Author)Duk-Soo Bae (Author)Ana Oaknin (Author)Isabelle Ray-Coquard (Author)Diane M. Provencher (Author)Beth Y. Karlan (Author)Catherine Lhommé (Author)Gary Richardson (Author)Dolores G. Rincón (Author)Robert L. Coleman (Author)Thomas J. Herzog (Author)Christian Marth (Author)Arija Brize (Author)Michel Fabbro (Author)Andrés Redondo (Author)Aristotelis Bamias (Author)Marjan Tassoudji (Author)Lynn Navale (Author)Douglas J. Warner (Author)Amit M. Oza (Author)
- Additional links
- http://dx.doi.org/10.1016/S1470-2045(14)70244-X
- Publication Details
- Lancet Oncology, Vol.15(8), pp.799-808
- Number of pages
- 799-808
- Identifiers
- 991005932225902656
- Academic Unit
- School of Medicine; Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Lancet Oncology, Vol.15(8), pp.799-808
2014
PMID: 24950985
Metrics
2 Record Views